Pomerantz Law Firm Announces the Filing of a Class Action Against Savara Inc. and Certain Officers – SVRA
Pomerantz LLP filed a class action lawsuit against Savara Inc. alleging false and misleading statements regarding its drug candidate, MOLBREEVI.Summary
Pomerantz LLP has announced a class action lawsuit against Savara Inc. and certain officers, alleging violations of federal securities laws between March 7, 2024, and May 23, 2025. The lawsuit claims Savara made materially false and misleading statements regarding the completeness of its Biologics License Application (BLA) for MOLBREEVI, a potential treatment for autoimmune pulmonary alveolar proteinosis (aPAP). Specifically, the complaint alleges the BLA lacked sufficient Chemistry, Manufacturing, and Controls (CMC) information, leading the FDA to issue a refusal-to-file letter. This resulted in a significant drop in Savara’s stock price and raised concerns about the company’s financial stability and need for additional capital. Investors who purchased Savara securities during the Class Period have until November 7, 2025, to seek appointment as Lead Plaintiff.
(Source：FinancialContent)